Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NLSPW - NLS Pharmaceutics Ltd - Warrants (25/09/2025)


Previous close
0.0132
0   0%

Share volume: 4,924
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$0.01
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-34.00%
1 Month
-56.00%
3 Months
-67.73%
6 Months
-73.60%
1 Year
-82.40%
2 Year
-91.51%
Key data
Stock price
$0.01
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.17
52 WEEK CHANGE
-$0.90
MARKET CAP 
5.319 M
YIELD 
N/A
SHARES OUTSTANDING 
3.636 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,544
AVERAGE 30 VOLUME 
$22,723
Company detail
CEO:
Region: US
Website: nlspharma.com
Employees: 7
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm

Recent news